All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, could circulating tumor cells (CTCs) and tumor DNA be more sensitive than a bone marrow (BM) aspirate to assess treatment response in MM?
Could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in MM?
In this video, Paiva discusses the importance of assessing treatment efficacy in myeloma. He also mentions minimal residual disease (MRD) assessments, next-generation sequencing (NGS) and next-generation flow (NGF).
Subscribe to get the best content related to multiple myeloma delivered to your inbox